The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat uncomplicated urinary tract infections (uUTIs). The drug, which is the first in a ...

Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 years. The FDA has approved GSK’s Blujepa (gepotidacin), a first-in-class oral ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa ...

This approval for Blujepa marks the introduction of a new class of oral antibiotics for uUTIs in nearly 30 years. Per GSK, the drug targets a different part of the bacteria than most existing ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract infections caused ...